Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers

被引:2
|
作者
Karim, Frederic [1 ]
Amin, Adina [1 ]
Liu, Marie [1 ]
Vishnuvardhan, Nivetha [2 ]
Amin, Saif [1 ]
Shabbir, Raffey [1 ]
Swed, Brandon [3 ]
Khan, Uqba [3 ]
机构
[1] New York Presbyterian Brooklyn Methodist Hosp, Internal Med, 506 6th St, Brooklyn, NY 11215 USA
[2] New York Presbyterian Brooklyn Methodist Hosp, Pediat Hematol Oncol, 506 6th St, Brooklyn, NY 11215 USA
[3] Weill Cornell Med, Hematol Oncol, 515 6th St, Brooklyn, NY 11215 USA
关键词
checkpoint inhibitors; esophageal cancer; gastric cancer; immunotherapy; PD-L1; HER2; clinical trials; HELICOBACTER-PYLORI INFECTION; ESOPHAGEAL CANCER; PLUS CHEMOTHERAPY; GASTRIC-CANCER; BARRETTS-ESOPHAGUS; 1ST-LINE TREATMENT; DOUBLE-BLIND; NIVOLUMAB; JUNCTION; HER2;
D O I
10.3390/cancers15164099
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This article reviews the essential clinical trials that have led to these immunother-apy approvals and explores the use of predictive biomarkers, such as PD-L1 expression and MSI status, to identify patients who are most likely to benefit from immunotherapies. Methods: This case review series describe findings from different clinical trials and contribute to the evolving understanding of the role of CPIs in managing advanced gastroesophageal cancers and may lead to improved treatment options and patient outcomes. Ongoing clinical trials also hold promise for expanding treatment options and improving patient outcomes in the future. Methods: The systematic review followed the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The protocol has not been registered. A systematic literature review was conducted to identify relevant clinical trials and studies that describe the role of immune checkpoint inhibitors in managing advanced gastroesophageal cancers. Electronic database (PubMed, Clinicaltri-als.gov, Society of Immunotherapy of Cancer, Aliment Pharmacology & Therapeutics, BMC cancer, Molecular Cancer Research, Nature Reviews Molecular Cell Biology, American Association for Cancer Research, Science, Nature, Cancer Discovery, Journal of the National Cancer Institute, Advanced Immunology, Oncotarget, Nature Medicine, Nature Genetics, Gut, Pathology and Oncology Research, Journal of Clinical Oncology, The New England Journal of Medicine, Gastrointestinal oncology, JAMA Oncology, Journal of Gastrointestinal Oncology, Current Oncology, Annals of Oncology, The Lancet, JCO Oncology Practice, Future Oncology, Gastric Cancer, CA: A Cancer Journal for Clinicians, American Journal of Gastroenterology, Gastroenterology, Journal of the National Cancer Institute, International Journal of Epidemiology, Helicobacter, Gastroenterology Review) were searched using a combination of relevant keywords and MESH terms. The search encompassed articles published up to 5/2023. Additionally, manual searches of reference lists of selected articles and pertinent review papers were conducted to ensure comprehensive coverage of relevant studies. Studies were included if they provided insights into clinical trials evaluating the efficacy and safety of CPIs in
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Checkpoint inhibitors in gastrointestinal cancers:Expectations and reality
    Hampig Raphael Kourie
    Samer Tabchi
    Marwan Ghosn
    [J]. World Journal of Gastroenterology, 2017, (17) : 3017 - 3021
  • [22] Update on immune checkpoint inhibitors in gynecological cancers
    Heong, Valerie
    Ngoi, Natalie
    Tan, David Shao Peng
    [J]. JOURNAL OF GYNECOLOGIC ONCOLOGY, 2017, 28 (02)
  • [23] An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers
    Castellano, Tara
    Moore, Kathleen N.
    Holman, Laura L.
    [J]. CLINICAL THERAPEUTICS, 2018, 40 (03) : 372 - 388
  • [24] Immune checkpoint inhibitors for refractory childhood cancers
    Widemann, Brigitte C.
    [J]. LANCET ONCOLOGY, 2020, 21 (01): : 14 - 15
  • [25] Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality
    Kourie, Hampig Raphael
    Tabchi, Samer
    Ghosn, Marwan
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (17) : 3017 - 3021
  • [26] The role of hypermutation and replication repair deficiency in response of childhood cancers to immune checkpoint inhibitors
    Tabori, Uri
    [J]. CANCER RESEARCH, 2018, 78 (19)
  • [27] Controversies on the possible role of immune checkpoint inhibitors in pediatric cancers: balancing irAEs and efficacy
    Nigro, Olga
    Ferrari, Andrea
    Casanova, Michela
    Orbach, Daniel
    Leruste, Amaury
    Gatz, Susanne A.
    Frappaz, Didier
    Massimino, Maura
    [J]. TUMORI JOURNAL, 2021, 107 (04): : 276 - 281
  • [28] Advances in the management of gastrointestinal cancers-an upcoming role of immune checkpoint blockade
    Goel, Gaurav
    Sun, Weijing
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [29] Application of immune checkpoint inhibitors for resectable gastric/gastroesophageal cancer
    Lin, Feizhi
    Chen, Yongming
    Huang, Bowen
    Ruan, Shenghang
    Lin, Jun
    Chen, Zewei
    Huang, Chunyu
    Zhao, Baiwei
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [30] The Role of Checkpoint Inhibitors in Glioblastoma
    Kunal Desai
    Anne Hubben
    Manmeet Ahluwalia
    [J]. Targeted Oncology, 2019, 14 : 375 - 394